drugset / Trial / NCT01992276
Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection
Phase 2
Withdrawn
Crucell Holland BV
Division of Microbiology and Infectious Diseases (DMID) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the rate of decline in quantitative viral load measured in hospitalized patients with Influenza A infection
Timeline
- Start
- 2013-12
- Primary completion
- 2014-10
- Completion
- 2015-02
Outcome
Outcome not reported
Stopped: “Due to preliminary efficacy results from an influenza challenge trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CR8020 | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | DIRIDAVUMAB | Monoclonal antibody | 30 mg/kg | Intravenous |